Coverage under healthcare and long-term care insurance in major EU countries
First written in FY2016. 16 of 25 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-11-12.
No other company in this theme has enough history to compare yet.
- 2026-11-12AdvancedResults
「In Germany, clinical trials aimed at obtaining public health insurance coverage for spinal cord injury have begun based on a decision by the G-BA (Federal Joint Committee), the decision-making body for the public health insurance system. Treatment of the first patient began in August 2026. In addition, the public health insurance reimbursement rate for the cost of using HAL in the clinical trial has been formally set at €334.71 per treatment session.」
ドイツの公的医療保険適用に向けた臨床試験が開始され、第1例目の治療実施と償還単価の正式決定まで進んだ。 - FY2027-H1AdvancedAnnual report
「In Germany, clinical trials aimed at obtaining public health insurance coverage for spinal cord injury have begun based on a decision by the G-BA (Federal Joint Committee), the decision-making body for the public health insurance system. Treatment of the first patient began in August 2026. In addition, the public health insurance reimbursement rate for the cost of using HAL in the clinical trial has been formally set at €334.71 per treatment session.」
Clinical trials aimed at public health insurance coverage for spinal cord injury in Germany have begun, and the first patient was treated in August 2026. The reimbursement rate for HAL use in the trial was also formally set at €334.71 per treatment session. - FY2026AdvancedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance. Selection of the clinical trial sites has now been completed, and preparations to begin the trial are progressing.」
Regarding statutory health insurance coverage in Germany for spinal cord injury, following G-BA's decision to conduct the clinical trial, the process advanced to completion of clinical trial site selection and preparations to begin the trial. - 2026-05-14AdvancedResults
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance. Selection of the clinical trial sites has now been completed, and preparations to begin the trial are progressing.」
ドイツの公的医療保険適用に向けた臨床試験は、従来の準備段階から治験実施施設の選定完了・治験開始準備へ進んでいる。 - FY2025-H1AdvancedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance, and preparations including the selection of a CRO are progressing.」
For the clinical trial toward statutory health insurance coverage in Germany for spinal cord injury, preparations have advanced from protocol preparation to the selection of a CRO and other preparatory steps. - FY2024-Q3RestatedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance, and preparations are progressing.」
We are reaffirming the status of preparations for the clinical trial decided by G-BA toward coverage under Germany's statutory health insurance for spinal cord injury. - FY2024-Q2AdvancedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance, and as of October 2023 was preparing the protocol.」
Toward coverage under Germany's statutory health insurance, following G-BA's decision to conduct the clinical trial, preparations for the protocol had advanced as of October 2023. - FY2024-Q1AdvancedAnnual report
「For spinal cord diseases, approval for additional indications was obtained in October 2022 for two diseases, viral HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia, and an application concerning medical fees and insurance coverage was submitted in July 2023.」
For HAM and hereditary spastic paraplegia, the process advanced to the application stage for medical fees and insurance coverage following approval of the additional indications. The document states that the application was submitted in July 2023. - FY2023-Q3AdvancedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, published the outline of a clinical trial protocol for spinal cord injury on the premise of coverage under statutory health insurance, and preparations for the clinical trial will now begin.」
Toward coverage under Germany's statutory health insurance, G-BA published the outline of the clinical trial protocol, advancing to the preparation stage. - FY2023-Q2AdvancedAnnual report
「In Germany, G-BA, the authority responsible for statutory health insurance, decided to conduct a clinical trial for spinal cord injury on the premise of coverage under statutory health insurance and is preparing the outline of the protocol.」
Toward coverage under Germany's statutory health insurance, G-BA decided to conduct a clinical trial for spinal cord injury, advancing to the stage of preparing the protocol outline. - FY2023-Q1AdvancedAnnual report
「For medical-use HAL® lower-limb type (bilateral-leg model), based on results demonstrating high efficacy and safety in a post-marketing use-results survey for slowly progressive neuromuscular intractable diseases, reimbursement for medical-use HAL® was approved for inpatients at DPC hospitals, which account for approximately 80% of designated hospitals for intractable diseases, under the fiscal 2022 medical fee revision, and the reimbursement points were increased. In response, we are promoting the adoption of medical-use HAL® in Japan.」
Following the survey results, the fiscal 2022 medical fee revision expanded the scope of reimbursement to include inpatients at DPC hospitals and increased the reimbursement points. The expansion of insurance coverage has advanced to the stage of being used for domestic adoption and procedures in countries around the world. - FY2022-Q3AdvancedAnnual report
「Based on the results of this post-marketing use-results survey, the Japanese Society of Neurological Therapeutics proposed a reassessment of medical fees, stating that "a remarkable functional improvement effect unprecedented in this field, including among already approved drugs, was confirmed in patients with slowly progressive neuromuscular intractable diseases for whom no other effective treatment has been established" (excerpt from the society's proposed medical technology evaluation proposal). As a result, the draft medical fee revision approved at the plenary meeting of the Central Social Insurance Medical Council (Chuikyo) held on 9 February 2022 provided for medical fees for medical-use HAL® to be claimable for inpatients at DPC hospitals, which account for approximately 80% of designated hospitals for intractable diseases, and announced an increase in the relevant reimbursement points.」
Following the results of the post-marketing use-results survey in Japan, a draft medical fee revision was approved that included reimbursement for inpatients at DPC hospitals and an increase in the reimbursement points. - FY2022-Q1AdvancedAnnual report
「For medical-use HAL® lower-limb type (bilateral-leg model), a post-marketing use-results survey for slowly progressive neuromuscular intractable diseases in Japan was completed in November 2020, covering 20 medical institutions, 218 patients and 6,486 treatments in total. The results demonstrated extremely high efficacy and safety in actual clinical use. By using these results in procedures for insurance coverage in countries around the world, we will accelerate the rollout of medical-use HAL® as a global standard treatment for progressive neuromuscular intractable diseases for which no globally effective treatment has been established.」
The post-marketing use-results survey was completed at a scale of 20 institutions, 218 patients and 6,486 treatments in total, and the results advanced to the stage of being used in procedures to obtain insurance coverage worldwide. - FY2020-Q2RestatedAnnual report
「In July 2019, Nürnberger, a major German insurance group, agreed with our subsidiary Cyberdyne Care Robotics GmbH to provide private insurance coverage in Germany for the first time for cybernics treatment using medical-use HAL®. In Poland, our partner medical institution Constance Care provides cybernics treatment under contracts with the major private insurers WARTA and PZU.」
We continue to disclose the agreement on the first private insurance coverage in Germany and the provision of treatment in Poland under contracts with private insurers. - FY2020-Q1AdvancedAnnual report
「In July 2019, Nürnberger, a major German insurance group, agreed with our subsidiary Cyberdyne Care Robotics GmbH to provide private insurance coverage in Germany for the first time for cybernics treatment using medical-use HAL®. In Poland, our partner medical institution Constance Care provides cybernics treatment under contracts with the major private insurers WARTA and PZU.」
An agreement was reached on private insurance coverage in Germany for the first time, and treatment in Poland advanced to the stage of being provided under contracts with major private insurers. - FY2019RestatedAnnual report
「Coverage is already available under statutory accident insurance in Germany and private insurance in Poland, and we are holding discussions to expand the scope of coverage to Germany's statutory and private health insurance and to coverage in other countries.」
Building on existing insurance coverage in Germany and Poland, we continue discussions on expanding coverage to Germany's statutory health insurance and other systems, as well as to other countries. - FY2019-Q1AdvancedAnnual report
「In Germany, statutory accident insurance covers treatment using medical-use HAL®, but we are pursuing various procedures to expand coverage to statutory health insurance. Outside Germany, the device has already been introduced at medical institutions in Poland, and discussions are also progressing toward adoption in other EU countries.」
While continuing procedures to expand coverage to Germany's statutory health insurance, we are broadening the scope of discussions toward adoption in EU countries other than Poland. - FY2018RestatedAnnual report
「Coverage is already available under statutory accident insurance in Germany and private insurance in Poland, and we are holding discussions to expand the scope of coverage to Germany's statutory and private health insurance and to coverage in other countries.」
We have indicated a policy of continuing to pursue expanded coverage under Germany's statutory health insurance and other systems, as well as insurance coverage in other countries. - FY2018-Q2RestatedAnnual report
「In Germany, statutory accident insurance covers treatment using medical-use HAL®, but we are pursuing various procedures to expand coverage to statutory health insurance. In Poland, private insurance coverage for cybernics treatment using medical-use HAL® began at medical institutions in July 2017.」
We continue to pursue procedures to expand coverage to Germany's statutory health insurance and disclose that private insurance coverage began in Poland in July 2017. - FY2018-Q1AdvancedAnnual report
「In Poland, private insurance coverage for cybernics treatment using medical HAL® began at a medical institution in July 2017. This was the first case in which a medical institution using medical HAL® entered into an agreement with a private insurance company covering cybernics treatment.」
Regarding the challenge of obtaining insurance coverage in the EU, we report concrete progress in that private insurance coverage for cybernics treatment using medical-use HAL began in Poland. - FY2017RestatedAnnual report
「To establish cybernics treatment using medical-use HAL® as a global standard of care in the EU, it is necessary to obtain coverage under the public and private health insurance systems of the EU's major countries and secure appropriate reimbursement points.」
Coverage under public and private insurance in major EU countries and the acquisition of appropriate reimbursement points remain ongoing challenges. - FY2017-Q3RestatedAnnual report
「In Germany, statutory accident insurance covers treatment using medical-use HAL®, but we are pursuing various procedures to expand coverage to statutory health insurance.」
We continue to pursue procedures to expand coverage to Germany's statutory health insurance. - FY2017-Q2RestatedAnnual report
「In Germany, statutory accident insurance covers treatment using medical-use HAL®, but we are pursuing various procedures to expand coverage to statutory health insurance.」
We continue to pursue procedures to expand coverage to Germany's statutory health insurance. - FY2017-Q1AdvancedAnnual report
「On 30 October 2015, we also submitted an application to G-BA (the Federal Joint Committee of Germany) concerning reimbursement for all patients with paraplegia who had completed the period corresponding to the acute and rehabilitation phases.」
In Germany, applications were submitted to InEK and G-BA seeking public health insurance coverage for patients from the acute through rehabilitation phases and for paraplegic patients thereafter. - FY2016First statedAnnual report
「To accelerate the expansion of distribution channels and volumes for the HAL® robotic suit as a globally standard healthcare, nursing and welfare device in the EU, it is necessary to obtain coverage and appropriate reimbursement points under the healthcare and long-term care insurance systems of the EU's major countries.」
In addition to distribution of the device within the EU, obtaining coverage under healthcare and long-term care insurance in major countries and securing appropriate reimbursement points remain expansion priorities.